+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Clostridium Difficile Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030

  • PDF Icon


  • April 2022
  • Region: Global
  • GlobalData
  • ID: 5624822
Clostridium Difficile Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Clostridium difficile Tests market for the year 2020 and beyond. Clostridium difficile is one of the major etiological agents for hospital acquired infections all over the world, especially in the US. The disease manifests itself in the form of prolonged Diarrhea and pseudo membranous colitis, often in patients who have recently stayed at a healthcare facility and/or have been using antibiotics for a significant length of time. Clostridium difficile Infection (CDI) occurs along with other comorbidities and frequently increases the length of stay in hospital, even after the primary disease has been cured.

The Clostridium difficile Tests includes Clostridium Difficile Culture Tests, Clostridium difficile Toxin Enzyme Immunoassay (EIA) Tests, Clostridium difficile Glutamate Dehydrogenase (GDH) Enzyme Immunoassay (EIA) Tests, Clostridium difficile Nucleic Acid Amplification Tests (NAATs) and Dual Toxin and GDH EIA Tests.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

  • Currently marketed Clostridium difficile Tests and evolving competitive landscape
  • Insightful review of the key industry trends.
  • Annualized total Clostridium difficile Tests market revenue by segment and market outlooks from 2015-2030.
  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, the analysts' provide unique country specific insights on the market.
  • SWOT analysis for Clostridium Difficile Tests market.
  • Competitive dynamics insights and trends provided for Clostridium Difficile Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system.

In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies Covered:

Danaher Corp, TechLab, Inc., Meridian Bioscience Inc, bioMerieux SA, Thermo Fisher Scientific Inc, LG Chem Ltd, Luminex Corp, Microbiologics Inc, American Type Culture Collection, DiaSorin SpA and others.

Countries Covered:

United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.


This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for
  • CMO executives who must have deep understanding of the Clostridium difficile Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:
  • Understand the impact of COVID-19 on Clostridium difficile Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Clostridium difficile Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Clostridium difficile Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Clostridium difficile Tests market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Danaher Corp
  • TechLab, Inc.
  • Meridian Bioscience Inc
  • bioMerieux SA
  • Thermo Fisher Scientific Inc
  • LG Chem Ltd
  • Luminex Corp
  • Microbiologics Inc
  • American Type Culture Collection
  • DiaSorin SpA